Literature DB >> 1392448

Mesna side effects which imitate vasculitis.

E Reinhold-Keller1, J Mohr, E Christophers, K Nordmann, W L Gross.   

Abstract

Mesna (sodium-2-mercaptoethansulfonate) is used in the prophylaxis of cyclophosphamide (CYC)-induced hemorrhagic cystitis. Four patients being treated with "low dose" CYC and prednisone for vasculitis developed severe side effects to Mesna. Fever, arthralgia, myalgia, tachycardia, electrocardiogram changes consistent with perimyocarditis, erythroderma, bullous skin and mucous membrane lesions, and abdominal complaints with profuse diarrhea were noted approximately 3 weeks after the initiation of therapy for CYC-induced leukopenia and a conservatively reduced prednisone dosage. Positive reexposure tests confirmed the association to Mesna use, and hypersensitivity skin tests demonstrated a delayed hypersensitivity reaction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1392448     DOI: 10.1007/bf00180290

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  19 in total

1.  Allergic reactions to mesna.

Authors: 
Journal:  Lancet       Date:  1991-08-10       Impact factor: 79.321

2.  Wegener's granulomatosis. Long-term followup of patients treated with cyclophosphamide.

Authors:  M J Reza; L Dornfeld; L S Goldberg; R Bluestone; C M Pearson
Journal:  Arthritis Rheum       Date:  1975 Sep-Oct

Review 3.  Mesna--a short review.

Authors:  I C Shaw; M I Graham
Journal:  Cancer Treat Rev       Date:  1987-06       Impact factor: 12.111

4.  Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis.

Authors:  T J Stillwell; R C Benson; R A DeRemee; T J McDonald; L H Weiland
Journal:  Arthritis Rheum       Date:  1988-04

5.  Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide.

Authors:  J V Donadio; K E Holley; R H Ferguson; D M Ilstrup
Journal:  N Engl J Med       Date:  1978-11-23       Impact factor: 91.245

6.  Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis.

Authors:  J F Fries; G C Sharp; H O McDevitt; H R Holman
Journal:  Arthritis Rheum       Date:  1973 Mar-Apr

7.  Long-term cyclophosphamide therapy in rheumatoid arthritis.

Authors:  W M Fosdick; J L Parsons; D F Hill
Journal:  Arthritis Rheum       Date:  1968-04

8.  Hypersensitivity to mesna.

Authors:  E Lang; M Goos
Journal:  Lancet       Date:  1985-08-10       Impact factor: 79.321

9.  Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up.

Authors:  S Carette; J H Klippel; J L Decker; H A Austin; P H Plotz; A D Steinberg; J E Balow
Journal:  Ann Intern Med       Date:  1983-07       Impact factor: 25.391

10.  Controlled trial of cyclophosphamide in rheumatoid arthritis.

Authors:  A S Townes; J M Sowa; L E Shulman
Journal:  Arthritis Rheum       Date:  1976 May-Jun
View more
  5 in total

1.  Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide?

Authors:  B Hellmich; I Kausch; C Doehn; D Jocham; K Holl-Ulrich; W L Gross
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

2.  [Secondary vasculitides and vasculitis mimics].

Authors:  K de Groot; E Märker-Hermann
Journal:  Z Rheumatol       Date:  2012-11       Impact factor: 1.372

Review 3.  Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.

Authors:  M Links; C Lewis
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

Review 4.  Hypersensitivity reactions to chemotherapeutic drugs.

Authors:  Gillian M Shepherd
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

Review 5.  A review of the use of chemoprotectants in cancer chemotherapy.

Authors:  C Lewis
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.